“It is vital we invest in fighting future variants of this disease as well as other deadly viruses that are circulating, such as seasonal flu and RSV, and this partnership with Moderna will also strengthen our ability to respond to any future pandemics.”
Yesterday the United Kingdom announced that have agreed to a new 10-year contract with pharmaceutical giant Moderna further research and develop new mRNA-based vaccines, which includes building a “state-of-the-art vaccine manufacturing centre with the ability to produce up to 250 million vaccines a year.”
Richard Torbett, Chief Executive, Association of the British Pharmaceutical Industry (ABPI), called this “fantastic news” and that this has the great possibility of being “a key growth driver for the UK economy.”
More specifically mRNA Covid vaccines will be produced, along with flu and respiratory syncytial virus (RSV) – which are the three diseases the media has been warning about these past two months, calling it a “tripledemic.”
